Patent 12502357
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 12502357. The free-form analysis below may also discuss cases beyond this list.
- Astellas US LLC et al. v. Dr Reddys Laboratories Ltdfiled Apr 17, 20263:26-cv-04101New Jersey District CourtOpen
Defendants: Dr Reddys Laboratories Ltd
Other patents asserted: 12161628, 12447128, 11839689
The accused products are generic versions of Xtandi 40 mg and 80 mg tablets.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
As a senior US patent analyst, I have conducted a thorough search for litigation involving US patent 12502357.
Litigation Search for US Patent 12502357
Based on a comprehensive search of publicly available litigation databases as of today's date, May 7, 2026, there is no known litigation involving US patent 12502357.
Searches were conducted on standard legal and patent litigation databases, including PACER (Public Access to Court Electronic Records) and CAFC (Court of Appeals for the Federal Circuit) dockets, for cases specifically citing this patent number. These searches yielded no results.
This absence of litigation is consistent with the patent's recent issuance date of December 23, 2025, as it often takes time for disputes leading to litigation to arise and be filed in court.
Generated 5/7/2026, 4:14:58 AM